RAPT Therapeutics, Inc.
RAPT
$7.33
-$0.67-8.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.22M | 8.01M | 6.45M | 6.69M | 7.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.27M | 54.47M | 19.79M | 29.33M | 32.52M |
| Operating Income | -19.27M | -54.47M | -19.79M | -29.33M | -32.52M |
| Income Before Tax | -17.17M | -53.25M | -18.43M | -27.66M | -30.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.17M | -53.25M | -18.43M | -27.66M | -30.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.17M | -53.25M | -18.43M | -27.66M | -30.52M |
| EBIT | -19.27M | -54.47M | -19.79M | -29.33M | -32.52M |
| EBITDA | -19.01M | -54.18M | -19.49M | -29.03M | -32.20M |
| EPS Basic | -0.64 | -9.12 | -3.79 | -5.69 | -6.32 |
| Normalized Basic EPS | -0.41 | -5.76 | -2.37 | -3.56 | -4.08 |
| EPS Diluted | -0.64 | -9.12 | -3.79 | -5.69 | -6.32 |
| Normalized Diluted EPS | -0.41 | -5.76 | -2.37 | -3.56 | -4.08 |
| Average Basic Shares Outstanding | 26.93M | 5.84M | 4.86M | 4.86M | 4.83M |
| Average Diluted Shares Outstanding | 26.93M | 5.84M | 4.86M | 4.86M | 4.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |